Remyelination therapies: a new direction and challenge in multiple sclerosis

@article{Plemel2017RemyelinationTA,
  title={Remyelination therapies: a new direction and challenge in multiple sclerosis},
  author={Jason R Plemel and Wei-Qiao Liu and V. Wee Yong},
  journal={Nature Reviews Drug Discovery},
  year={2017},
  volume={16},
  pages={617-634}
}
Multiple sclerosis is characterized by inflammatory activity that results in destruction of the myelin sheaths that enwrap axons. The currently available medications for multiple sclerosis are predominantly immune-modulating and do not directly promote repair. White matter regeneration, or remyelination, is a new and exciting potential approach to treating multiple sclerosis, as remyelination repairs the damaged regions of the central nervous system. A wealth of new strategies in animal models… CONTINUE READING
BETA

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 20 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 260 REFERENCES

Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis

  • Muraro, A P.
  • JAMA Neurol
  • 2017

a neuroreparative pharmacological treatment for multiple sclerosis

  • Medina-Rodriguez, E. M. et al. Promoting in vivo remyelination with sma molecules
  • Sci. Rep. 7, 43545
  • 2017

a randomised, placebocontrolled, phase 2 trial

  • Cadavid, D. et al. Safety, efficacy of opicinumab in acute optic neuritis RENEW
  • Lancet Neurol. 16, 189–199
  • 2017

a randomised, single-blind, phase II study

  • Schwartzbach, C. J. et al. Lesion remyelinating activity of GSK2395 sclerosis
  • J. Neurol. 264, 304–315
  • 2017

A mouse model for testing remyelinating therapies

  • Bai, B C.
  • Exp. Neurol. 283,
  • 2016

Similar Papers

Loading similar papers…